#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.

POST Online Media Lite Edition


Impax Laboratories announces leadership transition

Staff Writer |
Hayward, Ca., USA - December 21, 2016, Hayward, Ca., USA - Impax Laboratories, Inc., a specialty pharmaceutical company, announced that J. Kevin Buchi, a member of the Impax board of directors, has been appointed interim president and CEO.

The Company's Board has come to a mutual agreement with G. Frederick Wilkinson that Mr. Wilkinson separate from his positions as President and Chief Executive Officer and as a member of the Board, effective immediately.

Mr. Buchi currently serves as President, Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation.

Mr. Buchi intends to retire from his position as President and Chief Executive Officer of TetraLogic Pharmaceuticals at the end of the year commensurate with TetraLogic Pharmaceuticals' previously announced asset sale to Medivir AB, which transaction is currently expected to close by December 31, 2016.

Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012.

Before joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva in October 2011.

Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in December 2010.

In addition to serving as a director of Impax and TetraLogic Pharmaceuticals, he has since 2013 served as a director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia.

He has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S.


What to read next

Impax Laboratories appoints Richard A. Bierly to board
Impax Laboratories: CFO Arthur A. Koch to resign
Janet Vergis appointed to Impax Laboratories board